(San Diego, Calif., Oct. 25 2018) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has released MuBase 2.0.
MuBase is CrownBio’s proprietary, free-to-access online database featuring the world’s largest collection of validated and characterized murine immuno-oncology models. MuBase collates tumor pathology, genomic characterization, and in vivo pharmacology data for a large selection of immuno-oncology models; syngeneics, GEMM, tumor homografts, and humanized target models.
MuBase 2.0 centers around a large data release including baseline immune profiles and RNAseq on the Company’s exclusive MuPrime® tumor homografts, with 79 models readily available for immuno-oncology studies.
In addition, the platform boasts a redesigned navigation experience and provides a more user-friendly search with simplified data browsing functionality for gene expression. The improvements to MuBase 2.0 make it a powerful everyday tool for early stage in vivo pharmacology and immuno-oncology research.
“To successfully interrogate immuno-oncology preclinical models and advance novel biological agents, a detailed understanding of each model’s genetic and immunological features is paramount,” said Dr. Henry Li, Senior VP of Research and Innovation at Crown Bioscience.
“This ongoing investment in improving our open access databases demonstrates CrownBio’s commitment to providing the most relevant data for the most appropriate in vivo model for each drug discovery program,” said Jean Pierre Wery, CEO of Crown Bioscience.
To learn more about MuBase visit: https://www.crownbio.com/oncology/oncology-databases/mubase.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
For more information on CrownBio’s commitment to furthering the field drug discovery, visit https://www.crownbio.com
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Wins 2024 Fierce CRO Award for Excellence in Client Service and Partnership
Crown Bioscience wins 2024 Fierce CRO Award for excellence in client service, underscoring its commitment to innovative drug development partnerships.
Crown Bioscience Wins BioTech Breakthrough Award for Drug Development Innovation
Crown Bioscience's OrganoidXplore receives BioTech Award, revolutionizing oncology with advanced preclinical screening.
Prostate Cancer Breakthrough: Crown Bioscience Collaborates in €1.75M Eurostars Funded Project for Novel Liquid Biops...
Crown Bioscience, part of JSR Life Sciences, joins a €1.75M Eurostars project to develop a novel liquid biopsy for prostate cancer, enhancing treatment.
Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities
Crown Bioscience enhances its global presence with the expansion of its Singapore facility, featuring cutting-edge oncology models and imaging capabilities.
Crown Bioscience Partners with CTI to Support Consulting Services in Oncology Drug Development
Crown Bioscience announces a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting...